T. Rowe Price Investment Management, Inc. Biogen Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $162 Billion
- Q4 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 3,099,786 shares of BIIB stock, worth $437 Million. This represents 0.29% of its overall portfolio holdings.
Number of Shares
3,099,786
Previous 4,256,286
27.17%
Holding current value
$437 Million
Previous $825 Million
42.55%
% of portfolio
0.29%
Previous 0.5%
Shares
7 transactions
Others Institutions Holding BIIB
# of Institutions
1,007Shares Held
131MCall Options Held
1.77MPut Options Held
2.34M-
Vanguard Group Inc Valley Forge, PA16.7MShares$2.36 Billion0.05% of portfolio
-
Primecap Management CO Pasadena, CA16MShares$2.26 Billion1.94% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.05 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.4MShares$1.04 Billion0.05% of portfolio
-
Wellington Management Group LLP Boston, MA4.93MShares$695 Million0.14% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $20.3B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...